APGE

Bullish

Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis

Apogee Therapeutics shares increased significantly after announcing positive interim results from its global Phase 2 study of zumilokibart (APG777) fo...

MSN 2 weeks ago 0

Neutral

Certain Pre-Funded Warrants of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026.

Certain Pre-Funded Warrants of Apogee Therapeutics, Inc. are under a lock-up agreement set to expire on April 24, 2026. This lock-up period began on M...

marketscreener.com 2 weeks ago 0

Neutral

Apogee Therapeutics (APGE) CFO sells 2,000 shares under 10b5-1 plan

Apogee Therapeutics, Inc.'s CFO, Jane Henderson, sold 2,000 shares of common stock at $90.00 per share on April 16, 2026, totaling $180,000. This tran...

Stock Titan 3 weeks ago 0